Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Toni Braxton's 'He Wasn't Man Enough' has new life as Lifetime movie ...

Gen. Shaw sends troops into the sewage tunnels under Derry. The children send themselves there, too. Bad idea in both cases.

Arvinas shows strong ESR1-mutant data with limited scope, niche SERD competition, Pfizer uncertainty, and a high-risk ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

Experience a 20-day survival challenge in the rainforest of Vietnam, where primitive skills and natural resources are ...

TL;DR: Episode 5 of Welcome to Derry is the moment the series evolves from a slow-burn origin story into full-blown cosmic ...

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

This encouraging oncology development arrives at a pivotal moment for Eli Lilly's primary revenue drivers. On November 17, 2025, its main competitor, Novo Nordisk, announced price reductions for its ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...